ArriVent BioPharma (AVBP) Other financing activities (2023 - 2026)
ArriVent BioPharma (AVBP) posted Other financing activities of $149000.0 for Q1 2026, up 77.38% sequentially from $84000.0 in Q4 2025, and down 49.15% YoY from $293000.0 in Q1 2025.
ArriVent BioPharma (AVBP) Other financing activities (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Other financing activities for 4 years, with the latest figure at $149000.0 in Q1 2026.
- Quarterly Other financing activities fell 49.15% year-over-year to $149000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $358000.0 (down 61.21% YoY) and the FY2025 annual result came in at $502000.0, down 20.44% from the prior year.
- Other financing activities improved to $149000.0 in Q1 2026 per AVBP's latest filing, from $84000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $531000.0 in Q3 2024 and troughed at $1000.0 in Q1 2024.
- A 4-year average of $125846.2 and a median of $55000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2024 and 2025: Other financing activities tumbled 96.15% in 2024, then surged 29200.0% in 2025.
- Over 4 years, Other financing activities stood at $285000.0 in 2023, then slumped by 80.7% to $55000.0 in 2024, then surged by 52.73% to $84000.0 in 2025, then surged by 77.38% to $149000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $149000.0, $84000.0, and $49000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 853,000.00 |
| Jun 30, 2026 | 853,000.00 |
| Mar 31, 2026 | 149,000.00 |
| Mar 31, 2026 | 149,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |